These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37439269)

  • 1. Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having.
    Sharon E; Othus M; Quandt ZE
    Cancer; 2023 Sep; 129(18):2769-2770. PubMed ID: 37439269
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of type 2 diabetes mellitus.
    Murphy MB; Kitabchi AE
    Tenn Med; 2000 Nov; 93(11):398-402. PubMed ID: 11077883
    [No Abstract]   [Full Text] [Related]  

  • 3. Is it worth treating diabetes? Lessons from the UKPDS. United Kingdom Prospective Diabetes Study.
    Pontiroli AE; Folli F
    Acta Diabetol; 1998 Dec; 35(4):170-1. PubMed ID: 9934813
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K; Schokker E; Jacob L
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of pharmacologically treated type 2 diabetes mellitus in 2012-2016 in Greece: Real-World Data.
    Lalagkas PN; Polyzois S; Papanas N; Nena E; Vourli N; Kontogiorgis C; Constantinides T
    Prim Care Diabetes; 2022 Oct; 16(5):714-716. PubMed ID: 35927164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Criteria and guidelines for combined therapy of type 2 diabetes. 2004 consensus document].
    Goday Arno A; Franch Nadal J; Mata Cases M
    Med Clin (Barc); 2004 Jul; 123(5):187-97. PubMed ID: 15274798
    [No Abstract]   [Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Need to Change Regulatory Evaluation of Hypoglycemia in Trials of Diabetes Treatments.
    Klonoff DC; Fleming A; Gabbay R
    J Diabetes Sci Technol; 2020 Nov; 14(6):987-989. PubMed ID: 31744326
    [No Abstract]   [Full Text] [Related]  

  • 9. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions.
    Kato ET; Das SR; McGuire DK
    Trends Cardiovasc Med; 2021 Feb; 31(2):101-108. PubMed ID: 31982285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones--a means to endpoint intervention.
    Jerkins TW
    Tenn Med; 2000 Nov; 93(11):403-5. PubMed ID: 11077884
    [No Abstract]   [Full Text] [Related]  

  • 12. [Glycemic control and diabetic complications].
    Yamada Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():604-8. PubMed ID: 15999778
    [No Abstract]   [Full Text] [Related]  

  • 13. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
    Mannucci E; Monami M; Ceriello A; Rotella CM
    Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
    [No Abstract]   [Full Text] [Related]  

  • 14. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study.
    Ewart RM
    BMJ; 2001 Oct; 323(7317):854-8. PubMed ID: 11597972
    [No Abstract]   [Full Text] [Related]  

  • 15. RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes.
    Adams R; Daly N; Robertson E; Giordano GN
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00207. PubMed ID: 33855210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of glycemic control in diabetes in the CVOT era.
    Einhorn D
    J Diabetes; 2020 Jan; 12(1):4. PubMed ID: 31746129
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
    Ahmed A; Anker SD; Butler J; Bakris GL; Bhatt DL; Fonarow GC; Packer M
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):892-894. PubMed ID: 37996192
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
    Vural Keskinler M; Telci Caklili O; Oguz A
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894. PubMed ID: 37996194
    [No Abstract]   [Full Text] [Related]  

  • 19. [Screening for type 2 diabetes mellitus: more than looking for undiagnosed diabetes].
    González-Clemente JM
    Med Clin (Barc); 2004 Jul; 123(5):177-80. PubMed ID: 15274796
    [No Abstract]   [Full Text] [Related]  

  • 20. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes.
    Sciannameo V; Berchialla P; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2021 May; 20(1):103. PubMed ID: 33971880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.